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Introduction
============

Clonal haematopoiesis of indeterminate potential (CHIP), defined as the presence of an expanded somatic blood cell clone in subjects without other haematological abnormalities,[@ehz591-B1] has recently shown to increase with age and is associated with coronary artery disease (CAD) and coronary calcification.[@ehz591-B2]^,^[@ehz591-B3] Mechanistically, the most common mutated genes in CHIP, DNMT3A and TET2, were experimentally shown to regulate the inflammatory potential of circulating leucocytes.[@ehz591-B3] The incidence of calcified degenerative aortic valve (AV) stenosis increases with age[@ehz591-B6] and correlates with chronic inflammation.[@ehz591-B7] Moreover, the outcome of transcatheter aortic valve implantation (TAVI) was previously shown to be unfavourably influenced by a systemic inflammatory response.[@ehz591-B8] Therefore, it was the aim of the present study to assess the incidence of DNMT3A- and TET2-CHIP-driver mutations in patients with severe calcified AV stenosis and, more importantly, to associate its presence with the clinical outcome following TAVI.

Methods
=======

Study cohort
------------

A total of 287 consecutive patients undergoing TAVI for severe calcified AV stenosis at the University Hospital of the Goethe University, Frankfurt, Germany, between February 2017 and March 2019, were studied. Eight patients were excluded due to previous haematological diseases. Thus, the final cohort consisted of 279 patients. All patients provided written informed consent for both, the TAVI procedure as well as genetic testing of blood samples. The ethics review board approved the protocol, and the study complies with the Declaration of Helsinki.

Clinical data, echocardiographic findings, and laboratory data were prospectively collected. The single clinical endpoint was all-cause mortality.

Laboratory measurements
-----------------------

Peripheral venous blood samples were obtained pre-procedurally and analysed for standard inflammatory parameters, including total leucocyte counts (*n* = 279), high-sensitive C-reactive protein (*n* = 273), and serum interleukin-6 (IL-6) levels (*n* = 261). Serum high-sensitive troponin T and N-terminal pro brain natriuretic peptide (NT-proBNP) were assessed in 240 and 243 patients, respectively, prior to TAVI.

Enumeration of leucocyte subsets
--------------------------------

Multiparameter flow cytometric \[fluorescence activated cell sorting (FACS)\] analysis was performed in a total of 82 patients. Monocyte subset (classical, intermediate, and non-classical) counts were determined using a 6-colour TruCount Assay (BD Biosciences) as previously described.[@ehz591-B9] T-cell subpopulations were determined using eight-colour (T-cell effectors, 'CD4 Panel 1') and five-colour (Tregs, 'CD4 Panel 2') flow cytometric assays. T-cell gating and subclassification was performed based on established models.[@ehz591-B10]

Next-generation sequencing
--------------------------

Next-generation sequencing was commercially performed by MLLDxGmbH, München, Germany. In brief, DNA was isolated with the MagNaPure System (Roche Diagnostics, Mannheim, Germany) from mononuclear cells after lysis of erythrocytes. The patients' libraries were generated with the Nextera Flex for enrichment kit (Illumina, San Diego, CA, USA) and sequences for DNMT3A and TET2 enriched with the IDT xGen hybridization capture of DNA libraries protocol and customized probes (IDT, Coralville, IA, USA). The libraries were sequenced on an Illumina NovaSeq 6000 with a mean coverage of 2147× and a minimum coverage of 400×, reaching a sensitivity of 2%. Reads were mapped to the reference genome (UCSC hg19) using Isaac aligner (v2.10.12) and a small somatic variant calling was performed with Pisces (v5.1.3.60). Protein truncating variants were classified as mutation. Non-synonymous changes were included, if they were well annotated (several definite submissions to COSMIC, IRAC, or ClinVAR). Other non-protein truncating variants were defined as variants of uncertain significance.

Statistical analysis
--------------------

Continuous variables are presented as mean (SD) unless otherwise noted. Analysis of variance testing was used for comparison of continuous variables between groups. Categorical variables were compared by the χ^2^ test or Fisher's exact test as appropriate. Bonferroni correction was used for multiple testing as appropriate. For survival analysis within the individual groups, the Kaplan--Meier analyses were used. Log-rank testing was applied to compare survival analysis and a stepwise multivariable Cox proportional regression analysis was performed to account for the potential effect of confounding variables. Statistical analysis was performed with SPSS statistical software package, version 24.0.

Results
=======

Patient characteristics and detection of mutations
--------------------------------------------------

The clinical and echocardiographic characteristics of the patients are summarized in *Table [1](#ehz591-T1){ref-type="table"}*.

###### 

Baseline characteristics and echocardiographic findings in patients with DNMT3A/TET2 and without DNMT3A/TET2 CHIP-driver mutations

                                                   Total cohort (*n* = 279)   DNMT3A/TET2 (*n* = 93)         No-DNMT3A/TET2 (*n* = 186)      *P*-value
  ------------------------------------------------ -------------------------- ------------------------------ ------------------------------- -----------
  Age (years) (*n* = 279)                          83.0 (79.3--86.1)          83.2 (80.1--86.7) (*n* = 93)   82.9 (79.1--85.8) (*n* = 186)   0.179
  Sex (female) (%) (*n* = 279)                     42.7% (*n* = 119)          51.6% (*n* = 48)               38.2% (*n* = 71)                **0.032**
  BMI (kg/m^2^) (*n* = 279)                        26.2 (23.4--29.4)          25.5 (22.7--29.4) (*n* = 93)   26.5 (23.9--29.4) (*n* = 186)   0.147
  Hypertension (%) (*n* = 279)                     88.2% (*n* = 246)          91.4% (*n* = 85)               86.5% (*n* = 161)               0.238
  Diabetes (%) (*n =* 279)                         31.2% (*n =* 87)           30.1% (*n =* 28)               31.7% (*n =* 59)                0.784
  On insulin (%) (*n* = 279)                       9.3% (*n* = 26)            10.7% (*n* = 10)               8.6% (*n* = 16)                 0.560
  Previous myocardial infarction (%) (*n* = 279)   16.5% (*n* = 46)           17.2% (*n* = 16)               16.1% (*n =* 30)                0.820
  Previous PCI (%) (*n* = 279)                     40.9% (*n* = 114)          38.7% (*n =* 36)               41.9% (*n =* 78)                0.605
  Previous CABG (%) (*n =* 279)                    9.3% (*n* = 26)            10.7% (*n =* 10)               8.6% (*n =* 16)                 0.560
  Previous stroke (%) (*n =* 279)                  15.4% (*n =* 43)           19.3% (*n =* 18)               13.4% (*n =* 25)                0.197
  Previous TIA (%) (*n =* 279)                     3.6% (*n =* 10)            3.2% (*n =* 3)                 3.8% (*n =* 7)                  1.0
  Carotid artery disease (%) (*n =* 279)           18.3% (*n =* 51)           17.2% (*n =* 16)               18.8% (*n =* 35)                0.742
  Peripheral artery disease (%) (*n =* 279)        11.5% (*n =* 32)           10.7% (*n =* 10)               11.8% (*n =* 22)                0.790
  COPD (%) (*n =* 279)                             19.7% (*n =* 55)           18.3% (*n =* 17)               20.4% (*n =* 38)                0.670
  Atrial fibrillation (%) (*n =* 279)              47.3% (*n =* 132)          50.5% (*n =* 47)               45.7% (*n =* 85)                0.445
  NYHA III (*n =* 279)                             68.8% (*n =* 192)          72.0% (*n =* 67)               67.2% (*n =* 125)               0.411
  NYHA IV (*n =* 279)                              12.2% (*n =* 34)           15.0% (*n =* 14)               10.7% (*n =* 20)                0.301
  LVEF (*n =* 279)                                 60 (50--60)                60 (45--60) (*n =* 93)         60 (50--60) (*n =* 186)         0.237
  Pmean (mmHg) (*n =* 260)                         43 (32--53)                41 (30--53) (*n =* 88)         45 (34--53) (*n =* 172)         0.171
  Mitral valve insufficiency (\>II) (*n =* 274)    7.6% (*n =* 21)            8.7% (*n =* 8) (*n =* 92)      7.1% (*n =* 13) (*n =* 182)     0.648

Continuous variables are shown as mean (SD) and median (interquartile range). Categorical variables are shown as frequency (%). Statistically significant difference is shown in bold.

BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; Pmean, mean transvalvular pressure gradient; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.

Patients had a median age of 83 (79.3--86.1) years. Pre-dilation of the stenotic valve was performed in the majority of patients. Seventy-two patients received a balloon-expandable prosthesis and 206 a self-expandable valve, transfemorally. One patient underwent a balloon-valvuloplasty.

Ninety-three of the 279 (33.3%) patients were carriers of a DNMT3A- (*n* = 53) or a TET2- (*n* = 40) CHIP-driver mutation with a variant allele frequency (VAF) ≥ 2%, with 10 patients harbouring mutations in both genes. A detailed list including the type of mutation and VAF is provided in the [Supplementary material online, *Tables S1* and *S2*](#sup1){ref-type="supplementary-material"}. In accordance with previous reports in the general population,[@ehz591-B2] the prevalence of DNMT3A- and TET2-CHIP-driver mutations in the present cohort with severe AV stenosis increased with patient age from 25% (2 out of 8 patients) in the age group of 55--69 years, to 25.4% (17 out of 67) at age 70--79 years, to 34.7% (65 out of 187) at age 80--89 years, and finally to 52.9% (9 out of 17) at age 90--99 years*.* However, compared to published cohorts of unselected populations[@ehz591-B2] as well as patients with coronary heart disease,[@ehz591-B3] the frequency of the identified DNMT3A- and TET2-CHIP-driver mutations with a variant allele frequency ≥ 2% was considerably higher in all age groups. Thus, DNMT3A- and TET2-CHIP-driver mutations are enriched in patients with severe calcified AV stenosis undergoing TAVI.

Association between CHIP-driver mutations and baseline clinical and procedural characteristics
----------------------------------------------------------------------------------------------

*Tables [1](#ehz591-T1){ref-type="table"}*and** [*2*](#ehz591-T2){ref-type="table"} summarize the baseline pre-TAVI clinical characteristics and laboratory values for carriers and non-carriers of DNMT3A- and TET2-CHIP-driver mutations. As illustrated, there were no significant differences except for the slightly higher frequency of female patients in the DNMT3A- and TET2-CHIP-driver mutations group. However, neither risk factors for nor the presence of clinically manifest atherosclerotic vascular disease were different. Likewise, procedural characteristics as well as laboratory values did not differ between the two groups. NT-proBNP serum levels were slightly, but non-significantly elevated in carriers of DNMT3A/TET2-CHIP-driver mutations.

###### 

Laboratory parameters in patients with DNMT3A/TET2 and without DNMT3A/TET2 CHIP-driver mutations

                                           Total cohort (*n* = 279)   DNMT3A/TET2 (*n* = 93)           No-DNMT3A/TET2 (*n* = 186)      *P*-value
  ---------------------------------------- -------------------------- -------------------------------- ------------------------------- -----------
  C-reactive protein (mg/dL) (*n =* 273)   0.36 (0.15--0.99)          0.41 (0.16--0.98) (*n =* 92)     0.34 (0.14--1.01) (*n =* 181)   0.638
  Leucocytes (/nL) (*n =* 279)             7.1 (5.9--8.2)             6.8 (5.8--8.0) (*n =* 93)        7.2 (5.9--8.3) (*n =* 186)      0.254
  Interleukin 6 (pg/mL) (*n =* 261)        5.8 (3.5--13.0)            5.7 (3.8--12.0) (*n =* 88)       6.1 (3.4--13.1) (*n =* 173)     0.875
  Haemoglobin (g/dL) (*n =* 279)           11.9 ± 1.9                 11.7 ± 1.9 (*n =* 93)            12 ± 1.9 (*n =* 186)            0.246
  Haematocrit (%) (*n =* 279)              35.9 (31.7--38.9)          35.3 (31.1--38.8) (*n =* 93)     35.9 (32.0--39.0) (*n =* 186)   0.411
  Platelets (/nL) (*n =* 279)              214 (169--259)             210 (162--254) (*n =* 93)        218 (179--262) (*n =* 186)      0.316
  Creatinine (mg/dL) (*n =* 279)           1.15 (0.91--1.53)          1.18 (0.93--1.60) (*n =* 93)     1.12 (0.89--1.50) (*n =* 186)   0.164
  Urea (mg/dL) (*n =* 277)                 46 (34--63)                50 (35--65) (*n =* 91)           46 (34--62) (*n =* 186)         0.149
  NT-proBNP (pg/mL) (*n =* 243)            2069 (956--5095)           2244.5 (1139--6998) (*n* = 84)   1933 (880--4503) (*n* = 159)    0.058
  CK (U/L) (*n* = 275)                     71 (48--104)               84 (45--111) (*n* = 91)          69 (49--100) (*n* = 184)        0.460
  CK-MB (U/L) (=261)                       17 (14--22)                17 (14--21) (*n* = 82)           17 (13--23) (*n* = 179)         0.634
  Hs Troponin (pg/mL) (*n* = 240)          24 (15--45)                26 (17--57) (*n* = 79)           24 (14--40) (*n* = 161)         0.094

Continuous variables are shown as mean (SD) and median (interquartile range).

Prognostic significance of DNMT3A- and TET2-CHIP-driver mutations following transcatheter aortic valve implantation
-------------------------------------------------------------------------------------------------------------------

During the first 30 days after TAVI, 6 out of 186 no-DNMT3A/TET2-CHIP-driver mutation carriers (3.2%) and 2 (1 DNMT3A and 1 TET2) out of 93 DNMT3A/TET2-CHIP-driver mutation carriers (2.1%) died due to procedure-related complications.

In order to assess medium-term clinical outcome following TAVI, patients dying within the first 30 days after the procedure were excluded to avoid potential confounding effects of intra- or early post-TAVI complications leading to death. *[Take home figure](#ehz591-F1){ref-type="fig"}* illustrates that patients carrying a DNMT3A- or TET2-CHIP-driver mutation experienced a significantly worse clinical outcome for death during the first 8 months after TAVI. Since carriers of DNMT3A/TET2-CHIP-driver mutations were significantly more frequently female, we separately analysed the Kaplan--Meier survival curves for women and men. However, as illustrated in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Figure [1](#ehz591-F1){ref-type="fig"}*, there was no difference between female and male patients with respect to outcome and the log rank *P*-value adjusted for gender was 0.016. Thus, the difference in gender does not appear to confound our results that DNMT3A/TET2-CHIP-driver mutations are associated with increased mortality following TAVI. Likewise, when a stepwise multivariable Cox proportional regression analysis was performed to account for the potential effect of both age or sex, carrying a DNMT3A- or TET-2-CHIP-driver mutation remained independently associated with increased death in the medium-term follow-up after TAVI (HR 3.1, 95% CI 1.17--8.08; *P* = 0.022). Finally, further adjustment for NT-proBNP serum levels at baseline in addition to age and sex confirmed the independent association between the presence of DNMT3A/TET2-CHIP-driver mutations and death (HR 4.81, 95% CI 1.49--15.57; *P* = 0.009).

![Overall survival of patients with DNMT3A- or TET2-CHIP-driver mutations with a variant allele frequency ≥ 2% vs. patients without DNMT3A or TET2 mutations. ^\*^Patients with follow-up \<30 days have been excluded in order to remove mortality due to peri-procedural complications.](ehz591f2){#ehz591-F1}

Interestingly, although patients carrying a DNMT3A/TET2-mutation with a VAF \> 0.1 numerically showed a reduced 8-months survival (85.3%) compared to those with a VAF ≤ 0.1 (89.5%) and the no-CHIP patients (96.1%), the overall number of events is insufficient to firmly establish a dose--response relationship between VAF and subsequent death following successful TAVI.

In order to assess, whether the increase in the observed mortality may be confounded by the presence of concomitant atherosclerotic disease, atrial fibrillation or increased New York Heart Association (NYHA) class, we tested all individual components as well as the extent of atherosclerotic disease defined as involving one vascular bed (=CAD), two vascular territories \[defined as CAD plus peripheral arterial occlusive disease (PAOD) or cerebrovascular disease\], and three vascular territories (CAD, PAOD, and cerebrovascular disease). As summarized in *Table [3](#ehz591-T3){ref-type="table"}*, neither the presence of atrial fibrillation or increased NYHA class nor the extent of polyvascular atherosclerosis were significantly associated with clinical outcome. Moreover, there was no difference with respect to the prevalence of polyvascular disease between carriers of a DNMT3A/TET2-CHIP-driver mutation and no-CHIP patients, with 52.8% in no-CHIP vs. 47.2% in DNMT3A/TET2-CHIP-driver mutation carriers (*P* = 0.44) in one bed, 15.7% vs. 21.9% (*P* = 0.24) in two territories, respectively, and 5.6% vs. 3.3% (*P* = 0.55), respectively, in three territories affecting polyvascular atherosclerotic disease. Thus, in the present cohort with severe aortic stenosis, patients harbouring a DNMT3A/TET2-CHIP-driver mutation do not appear to be enriched for polyvascular atherosclerosis nor did the different manifestations of atherosclerosis affect outcome in the mid-term following TAVI.

###### 

Association of CHIP-mutations, polyvascular bed disorders and risk factors with clinical outcome

                                                                              95% CI for HR   
  ------------------------------ -------- ------- ------- ----------- ------- --------------- -------
  DNMT3A/TET2                    1.146    0.484   5.617   **0.018**   3.145   1.219           8.114
  Vascular beds                                                                               
   1                             −0.818   0.532   2.360   0.124       0.441   0.155           1.253
   2                             −0.099   0.636   0.024   0.876       0.906   0.260           3.152
   3                             0.091    1.029   0.008   0.930       1.095   0.146           8.231
  NYHA (III/IV)                  0.711    0.750   0.899   0.343       2.037   0.468           8.862
  Previous atrial fibrillation   0.118    0.471   0.063   0.802       1.126   0.447           2.836

Statistically significant difference is shown in bold.

1 vascular bed = coronary artery disease.

2 vascular beds = coronary artery disease and cerebrovascular disease or peripheral arterial occlusive disease.

3 vascular beds = coronary artery disease, cerebrovascular disease and peripheral arterial occlusive disease.

NYHA, New York Heart Association.

Potential mechanistic insights into increased mortality of CHIP carriers after transcatheter aortic valve implantation
----------------------------------------------------------------------------------------------------------------------

Differential myeloid and T-cell distributions were analysed pre-TAVI by FACS in a subset of 82 patients, of whom 15 carried a DNMT3A- and 13 a TET2-CHIP mutation. FACS analysis was performed without knowing the CHIP status of the patients. There were no differences between the three groups with respect to total counts of neutrophils, monocytes, total T cells, and the CD4^**+**^ T-cell subset. However, as illustrated in *Figure [1](#ehz591-F2){ref-type="fig"}*, patients harbouring a DNMT3A-CHIP-driver mutation demonstrated a significantly increased Th17/T reg ratio indicating a pro-inflammatory T-cell polarization, whereas patients harbouring a TET2-CHIP-driver mutation exhibited increased levels of circulating non-classical monocytes (CD14^dim^CD16^++^), which are known to secrete high levels of pro-inflammatory cytokines. While the increased Th17/Treg ratio remained statistically significant after Bonferroni correction to account for multiple testing with a *P*-value of 0.023, the difference in non-classical monocytes was no longer statistically significant most likely due to the limited number of patients studied in this subanalysis. Thus, these exploratory analyses may indicate that both mutations confer a heightened inflammatory state, albeit by different mechanisms.

![(*A*) Th17/T reg ratio in carriers of a DNMT3A-CHIP-driver mutation and patients without DNMT3A/TET2-mutations. (*B*) Number of non-classical monocytes in carriers of TET2-CHIP-driver mutations and patients without TET2/DNMT3A mutations. TAVI, transcatheter aortic valve implantation.](ehz591f1){#ehz591-F2}

Discussion
==========

This is the first study to investigate the occurrence of acquired somatic mutations in the most commonly mutated CHIP-driver genes DNMT3A and TET2 in patients with severe degenerative AV stenosis. Our results demonstrate that DNMT3A- or TET2-CHIP-driver mutations occur frequently in this patient population with advanced age, appear to be associated with increases in pro-inflammatory subsets of circulating leucocytes, and confer a profound increase in mortality even after successful correction of the AV stenosis by TAVI.

The results of the present study significantly extend previous reports showing that CHIP-driver mutations increase with age in healthy subjects,[@ehz591-B2] are associated with the risk and prognosis of patients with CAD,[@ehz591-B3] and may contribute to the progression of chronic heart failure.[@ehz591-B11] Importantly, when using the classical definition of CHIP as a variant allele frequency of the mutation ≥ 2%,[@ehz591-B1] the age-adjusted prevalence of DNMT3A- or TET2-CHIP-driver mutations appears to be significantly higher in the present study cohort compared with previously published data in age-matched patients with CAD[@ehz591-B3] as well as compared to our own report in patients with chronic heart failure.[@ehz591-B11] Since both TET2- and DNMT3A loss-of-function in murine models of heart disease were experimentally shown to activate the inflammasome complex[@ehz591-B3] and to promote fibrosis development,[@ehz591-B12] both of which are of fundamental importance for developing degenerative AV stenosis,[@ehz591-B13]^,^[@ehz591-B14] it is tempting to speculate that DNMT3A or TET2-CHIP-driver mutations have contributed to the development of severe AV stenosis.

Our extensive profiling for circulating inflammatory serum markers did not identify any differences between carriers of a DNMT3A- or TET2-CHIP-driver mutation and non-carriers, which is in agreement with previous studies in patients with CAD[@ehz591-B3] or chronic heart failure.[@ehz591-B11] However, when we assessed the inflammatory phenotype of specific circulating subsets of leucocytes in a subset of our patient population, it became apparent that patients carrying a DNMT3A-CHIP-driver mutation demonstrated a significantly elevated ratio of the pro-inflammatory Th17 cells over the anti-inflammatory regulatory T cells, whereas patients carrying a TET2-CHIP-driver mutation showed increased levels of so-called non-classical monocytes, which accumulate under various chronic inflammatory conditions and secrete high levels of pro-inflammatory cytokines, including tumour necrosis factor (TNF) α, IL-1β, and IL-8.[@ehz591-B15] Indeed, very recent studies in subjects with CHIP disclosed that single DNMT3A or TET2 mutated individuals had different lineage restriction patterns, with DNMT3A mutations affecting all haematopoietic lineages including T cells, whereas TET2 mutation was associated with myeloid restriction and mostly affected monocytes, but not T cells.[@ehz591-B16]^,^[@ehz591-B17] These observations may also reconcile the seemingly contradictory findings that the DNA methyltransferase DNMT3A exerts similar pro-inflammatory effects as the DNA demethylase TET2. However, given that profiling of specific subsets of leucocytes was performed only in a subset of our patient population, these results should be regarded as hypothesis-generating and need to be confirmed in larger patient cohorts.

Strikingly, patients carrying either a DNMT3A- or a TET2-CHIP-driver mutation demonstrated profoundly increased mortality during medium-term follow-up even after successful replacement of the stenotic AV by TAVI and excluding the first 30 days after the procedure to eliminate potential confounding factors introduced by the TAVI procedure itself, e.g. vascular complications, renal impairment, major bleeding, and ischaemia during rapid pacing and balloon-expandable valve implantation. Since DNMT3A- and TET2-CHIP-driver mutation carriers did not differ from non-DNMT3A/TET2-mutation carriers with respect to the presence and extent of atherosclerotic disease, risk factors for atherosclerosis, and other co-morbidities, the increased mortality cannot be attributed to those potentially confounding factors. Thus, the present study extends previous observations in CAD[@ehz591-B3] as well as chronic heart failure[@ehz591-B11] and further establishes DNMT3A- and TET2-CHIP-driver mutations as an important risk factor for the progression of cardiovascular disease.

Conclusion
==========

Our data support the hypothesis that acquired somatic mutations in haematopoietic cells due to mutations in the most common CHIP-driver genes DNMT3A and TET2 may be significantly associated with the progression of degenerative AV stenosis and a worse clinical mid-term outcome even after successful valve replacement by TAVI. Future studies will have to validate our findings in larger cohorts and test whether a targeted anti-inflammatory therapy may be a valuable treatment strategy in carriers of DNMT3A- or TET2-CHIP-driver mutations with severe degenerative AV stenosis undergoing TAVI.

Supplementary Material
======================

###### 

Click here for additional data file.
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